Search
Aclaris Therapeutics Inc
ACRSAdd to Watchlist
5.380USD
+0.120+2.28%
Close 09-23 16:00（ET）
751.37MMarket Cap
LossP/E TTM
Aclaris Therapeutics Inc (ACRS) Stock Price Target & Forecast
Analyst Rating
Based on 12 analysts giving stock ratings to Aclaris Therapeutics Inc in the past month.
Buy
6 Strong Buy
5 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
9.958USD+89.32%
ACRS Analyst Recommendation Trends
In the current month, ACRS has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ACRS average Analyst price target in the last month is 9.958.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
6
6
5
4
4
3
3
3
5
5
4
4
4
4
3
3
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
10
9
9
8
7
7
ACRS Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ACRS EPS is projected to reach -0.165 in FY2026Q3, following reported EPS of -0.151 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.15
-0.16
-0.16
-0.16
-0.17
Actual
-0.16
-0.15
-0.15
--
--
Surprise
-7.58%
+2.46%
+5.84%
--
--
FAQs
What is Aclaris Therapeutics Inc's expected revenue for the next quarter?
Aclaris Therapeutics Inc's expected revenue is 1.30M.
What is Aclaris Therapeutics Inc's price target?
Analysts forecast that Aclaris Therapeutics Inc's price target is USD 9.96, with the highest forecast at USD 16.00 and the lowest forecast at USD 4.00.
How have Aclaris Therapeutics IncACRS's recent earnings per share performed?
The market expectation was USD -0.15, while Aclaris Therapeutics IncACRS's earnings per share (EPS) for the previous quarter was USD -0.15. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Aclaris Therapeutics Inc?
Based on the ratings of Aclaris Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.